Want to take quizzes and track your credits?
A widely publicized press release and subsequent preliminary report of the RECOVERY trial, a randomized study conducted in the UK, noted a survival benefit with the use of dexamethasone in hospitalized patients with coronavirus disease 2019 (COVID-19).1 The use of dexamethasone for management of COVID-19 has already increased, particularly given the recent National Institutes of Health COVID-19 Treatment Panel guidelines that recommend its use.2
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: William M. Stauffer, MD, MSPH, Department of Medicine, University of Minnesota, 420 Delaware St SE, MMC 250, Minneapolis, MN 55455 (firstname.lastname@example.org).
Published Online: July 30, 2020. doi:10.1001/jama.2020.13170
Conflict of Interest Disclosures: Dr Stauffer reported serving as the lead medical advisor of the Immigrant, Refugee, and Migrant Health Branch at the CDC, where he has been an author on the refugee predeparture and postarrival parasitic screening and presumptive treatment guidelines, and has received royalties from UpToDate. Dr Walker reported receiving royalties from Elsevier and UpToDate outside the submitted work. No other disclosures were reported.
Disclaimer: The views expressed herein are the opinions of the authors and do not represent the position of the CDC, which did not participate in the development of this article, or any organization with which the authors are affiliated.
You currently have no searches saved.
You currently have no courses saved.